Journal
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
Volume 11, Issue 6, Pages 331-336Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejpn.2007.03.010
Keywords
vigabatrin infantile spasms; west syndrome; tuberous sclerosis; focal cortical dysplasia; epileptic encephalopathy
Categories
Ask authors/readers for more resources
Vigabatrin (VGB), a selective irreversible inhibitor of gamma-aminobutyric acid transaminase, has proved to be effective against cryptogenic and symptomatic infantile spasms (IS). Unfortunately, reports of serious visual field defects have led to a drastic reduction in the use of the drug. This review is based on a systematic search in the literature for evidence regarding efficacy and safety of VGB in IS. Based on a specific mechanism of action, there is a solid evidence of clinical efficacy of VGB in children with Tuberous Sclerosis. Similarly, VGB could represent a potential effective therapy also for spasms due to focal cortical dysplasia. In infants with spasms due to other causes, the risk of ophthalmologic toxicity should be carefully weighted against the benefit of controlling spasms. (C) 2007 Published by Elsevier Ltd. on behalf of European Paediatric Neurology Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available